Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Other Accumulated Expenses (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Other Accumulated Expenses for 4 consecutive years, with $8.2 million as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, Other Accumulated Expenses changed N/A year-over-year to $8.2 million, compared with a TTM value of $8.2 million through Mar 2024, changed N/A, and an annual FY2022 reading of $8.0 million, up 25.31% over the prior year.
  • Other Accumulated Expenses was $8.2 million for Q1 2024 at Cytek Biosciences, up from $8.0 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $8.2 million in Q1 2024 and bottomed at $2.0 million in Q3 2021.
  • Average Other Accumulated Expenses over 4 years is $5.7 million, with a median of $5.7 million recorded in 2021.
  • Peak annual rise in Other Accumulated Expenses hit 142.12% in 2022, while the deepest fall reached 25.31% in 2022.
  • Year by year, Other Accumulated Expenses stood at $4.6 million in 2020, then soared by 37.31% to $6.4 million in 2021, then increased by 25.31% to $8.0 million in 2022, then increased by 3.37% to $8.2 million in 2024.
  • Business Quant data shows Other Accumulated Expenses for CTKB at $8.2 million in Q1 2024, $8.0 million in Q4 2022, and $4.9 million in Q3 2022.